TPMPA

Pricing Availability   Qty
Cat.No. 1040 - TPMPA | C6H12NO2P | CAS No. 182485-36-5
Description: Selective GABAA-ρ antagonist
Chemical Name: (1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid
Purity: ≥98% (HPLC)
Datasheet
Citations (12)
Reviews (1)
Literature (4)

Biological Activity for TPMPA

TPMPA is a selective, competitive GABAA-ρ antagonist with only minimal effects on GABAA and GABAB receptors (Kb values are 2.1 μM (antagonist), 320 μM (antagonist) and EC50 ~ 500 μM (weak agonist) respectively). Displays 8-fold selectivity for human recombinant ρ1 receptors over ρ2 receptors.

Technical Data for TPMPA

M. Wt 161.14
Formula C6H12NO2P
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 182485-36-5
PubChem ID 5520
InChI Key MFUKVPOVVKKLRQ-UHFFFAOYSA-N
Smiles OP(C1=CCNCC1)(C)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for TPMPA

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 100

Preparing Stock Solutions for TPMPA

The following data is based on the product molecular weight 161.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 6.21 mL 31.03 mL 62.06 mL
5 mM 1.24 mL 6.21 mL 12.41 mL
10 mM 0.62 mL 3.1 mL 6.21 mL
50 mM 0.12 mL 0.62 mL 1.24 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for TPMPA

Certificate of Analysis / Product Datasheet
Select another batch:

References for TPMPA

References are publications that support the biological activity of the product.

Chebib et al (1998) GABAC receptor antagonists differentiate between human r1 and r2 receptors expressed in Xenopus oocytes. Eur.J.Pharmacol. 357 227 PMID: 9797041

Ragozzino et al (1996) Design and in vitro pharmacology of a selective γ-aminobutyric acidc receptor antagonist. Mol.Pharmacol. 50 1024 PMID: 8863850

Xu et al (2009) The involvement of GABA-C receptors in paired pulse depression of inhibitory postsynaptic currents in rat hippocampal CA1 pyramidal neurons. Exp.Neurol. 216 243 PMID: 19100735

Murata et al (1996) The first selective antagonist for a GABAc receptor. Bioorg.Med.Chem.Lett. 6 2073


If you know of a relevant reference for TPMPA, please let us know.

View Related Products by Target

View Related Products by Product Action

View all GABAA-ρ Receptor Antagonists

Keywords: TPMPA, TPMPA supplier, Selective, GABAC, antagonists, Receptors, GABAA-rho, GABAA-ρ, GABA-A, 1040, Tocris Bioscience

12 Citations for TPMPA

Citations are publications that use Tocris products. Selected citations for TPMPA include:

Lindstrom et al (2010) Retinal input to efferent target amacrine cells in the avian retina. J Neurosci 27 103 PMID: 20650017

Olmos-Serrano et al (2010) Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. Br J Pharmacol 30 9929 PMID: 20660275

Elgueta et al (2015) Acetylcholine induces GABA release onto rod bipolar cells through heteromeric nicotinic receptors expressed in A17 amacrine cells. J Neurosci 9 6 PMID: 25709566

Gascon et al (2006) GABA regulates dendritic growth by stabilizing lamellipodia in newly generated interneurons of the olfactory bulb. J Neurosci 26 12956 PMID: 17167085


Do you know of a great paper that uses TPMPA from Tocris? Please let us know.

Reviews for TPMPA

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used TPMPA?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Used in inhibitor cocktail.
By Anonymous on 12/03/2019
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: Retinal rod bipolar cells

Retinal dissections were performed in HEPES-buffered extracellular solution containing inhibitor cocktail50 umol/L

PMID: 30338673
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Ion Channel

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Pain

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
GABA Receptors

GABA Receptors Scientific Review

Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.